Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 18/20 | 0.69 |
| ▸ | DPP4 | P27487 | 18/20 | 0.69 |
| ▸ | PREP | P48147 | 9/20 | 0.69 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.69 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.69 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13263677 | 1.00 | FAP (0.69) | FAPDPP4PREPDPP8DPP9 | |
| SCHEMBL23876519 | 0.87 | FAP (0.53) | FAPDPP4PREPDPP8DPP9 | |
| SCHEMBL13263779 | 0.82 | FAP (0.74) | FAPDPP4PREPDPP8DPP9 | |
| SCHEMBL15130472 | 0.81 | DPP4 (1.00) | FAPDPP4PREPDPP8DPP9 | |
| SCHEMBL10022738 | 0.81 | DPP4 (1.00) | FAPDPP4PREPDPP8DPP9 | |
| SCHEMBL14161092 | 0.81 | DPP4 (0.63) | FAPDPP4PREPDPP8DPP9 | |
| SCHEMBL10022736 | 0.81 | FAP (0.75) | FAPDPP4PREPDPP8DPP9 | |
| SCHEMBL8286531 | 0.81 | FAP (0.72) | FAPDPP4PREPDPP8DPP9 | |
| SCHEMBL13713814 | 0.79 | DPP4 (0.65) | FAPDPP4PREPDPP8DPP9 | |
| SCHEMBL15335279 | 0.79 | FAP (0.63) | FAPDPP4PREPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| US-7998997-B2 | Inhibitors of fibroblast activation protein alpha | TRUSTEES OF TUFTS COLLEGE (US) | 2011-08-16 | — | — | US | disclosed |
| US-20090221818-A1 | Inhibitors of Fibroblast Activation Protein Alpha | TRUSTEES OF TUFTS COLLEGE (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | FAP 29/4885DPP4 3252/4885PREP 3414/4885 |
| US-20090221818-A1 | Inhibitors of Fibroblast Activation Protein Alpha | FIBP, FAP, BCAP31 | FAP 2/4885DPP4 2154/4885PREP 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.